You just read:

Five-Year Follow-Up Data for SPRYCEL(R) (dasatinib) 100 mg Once Daily Demonstrated 78 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib Mesylate[*]

News provided by

Bristol-Myers Squibb

10 Jun, 2011, 17:20 BST